litlas
Log inCreate account

Naim Alkhouri

Active 2009–2026

156
Papers
18,686
Citations
75
h-index
142
i10-index

Citations

Citations per year for Naim Alkhouri1983: 1 citations1997: 2 citations1999: 1 citations2009: 4 citations2010: 13 citations2011: 28 citations2012: 58 citations2013: 57 citations2014: 71 citations2015: 54 citations2016: 85 citations2017: 68 citations2018: 70 citations2019: 310 citations2020: 643 citations2021: 884 citations2022: 968 citations2023: 1,020 citations2024: 2,154 citations2025: 1,716 citations2026: 103 citations1984–1996: no citations, so these years are not shown1998: no citations, so this year is not shown2000–2008: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,039 citing papers, 21.1% of this breakdownChina: 1,229 citing papers, 12.7% of this breakdownUnited Kingdom: 576 citing papers, 6% of this breakdownItaly: 530 citing papers, 5.5% of this breakdownGermany: 426 citing papers, 4.4% of this breakdownFrance: 337 citing papers, 3.5% of this breakdownSpain: 309 citing papers, 3.2% of this breakdownJapan: 259 citing papers, 2.7% of this breakdownSouth Korea: 243 citing papers, 2.5% of this breakdownAustralia: 237 citing papers, 2.5% of this breakdownCanada: 236 citing papers, 2.4% of this breakdownIndia: 187 citing papers, 1.9% of this breakdown
0%21.1%Other 31.6%

Institutions

Fields

  • Medicine82.3%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Immunology and Microbiology1.8%
  • Engineering1.5%
  • Neuroscience0.7%
  • Nursing0.5%
  • Other1.9%

Topics

  • Liver Disease Diagnosis and Treatment24.2%
  • Liver Disease and Transplantation6.5%
  • Diet, Metabolism, and Disease6.5%
  • Liver Diseases and Immunity3.3%
  • Alcohol Consumption and Health Effects2.8%
  • Diabetes, Cardiovascular Risks, and Lipoproteins2.8%
  • Other53.9%

Coauthors

All papers

Open in search
  1. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

    Authors: Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, Jörn M. Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E. Moussa, Guy Neff, Mary E. Rinella, Quentin M. Anstee, Manal F. Abdelmalek, Zobair M. Younossi, Seth J. Baum, Sven Francque, Michael Charlton, Philip N. Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M. Pericàs, Rashmee Patil, Arun J. Sanyal, Mazen Noureddin, Meena B. Bansal, Naim Alkhouri, Laurent Castéra, Madhavi Rudraraju, Vlad Ratziu - New England Journal of Medicine 2024 cited by 1,701

  2. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

    Authors: Sven Francque, Pierre Bédossa, Vlad Ratziu, Quentin M. Anstee, Elisabetta Bugianesi, Arun J. Sanyal, Rohit Loomba, Stephen A. Harrison, R. Balabanska, Lyudmila Mateva, Nicolas Lanthier, Naim Alkhouri, Christophe Moreno, Jörn M. Schattenberg, Diana Stefanova-Petrova, Luisa Vonghia, Régine Rouzier, Maéva Guillaume, Alexander Hodge, Manuel Romero‐Gómez, Philippe Huot-Marchand, Martine Baudin, Marie‐Paule Richard, Jean‐Louis Abitbol, Pierre Broqua, Jean‐Louis Junien, Manal F. Abdelmalek - New England Journal of Medicine 2021 cited by 721

  3. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

    Authors: Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley, Deepak L. Bhatt, Naim Alkhouri, Juan P. Frías, Pierre Bédossa, Stephen A. Harrison, Donald J. Lazas, Robert J. Barish, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, Manal F. Abdelmalek - New England Journal of Medicine 2023 cited by 442

  4. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

    Authors: Stephen A. Harrison, Rebecca Taub, Guy Neff, K. Lucas, Dominic Labriola, Sam E. Moussa, Naim Alkhouri, Mustafa R. Bashir - Nature Medicine 2023 cited by 391

  5. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

    Authors: Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, Guy Neff, Eric Lawitz, Elisabetta Bugianesi, Quentin M. Anstee, Samina Ajaz Hussain, Philip N. Newsome, Vlad Ratziu, Azadeh Hosseini‐Tabatabaei, Jörn M. Schattenberg, Mazen Noureddin, Naim Alkhouri, Ramy Younes - New England Journal of Medicine 2024 cited by 423

  6. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, Rong Zhou, Cynthia A. Moylan, Juan P. Frías, Naim Alkhouri, Meena B. Bansal, Seth J. Baum, Brent A. Neuschwander‐Tetri, Rebecca Taub, Sam E. Moussa - The Lancet 2019 cited by 765

  7. Challenges and opportunities in NASH drug development

    Authors: Stephen A. Harrison, Alina M. Allen, Julie Dubourg, Mazen Noureddin, Naim Alkhouri - Nature Medicine 2023 cited by 345

  8. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

    Authors: Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Natalie Bzowej, Raj Vuppalanchi, Ziad Younes, Anita Kohli, Shiv Kumar Sarin, Stephen H. Caldwell, Naim Alkhouri, Mitchell L. Shiffman, Marianne Camargo, Georgia Li, Kathryn Kersey, Catherine Jia, Yanni Zhu, C. Stephen Djedjos, G. Mani Subramanian, Robert P. Myers, Nadege Gunn, Aasim Sheikh, Quentin M. Anstee, Manuel Romero‐Gómez, Michael Trauner, Zachary Goodman, Eric Lawitz, Zobair M. Younossi, Adrián Gadano, Marcelo Martins, Peter Angus, John Bate, Mark Danta, Jacob George, Alexander Hodge, Nickolas Kontorinis, S.A. Roberts, Santosh Sanagapalli, Richard Skoien, Alexander Thompson, Amany Zekry, Rudolf Stauber, Michael Trauner, Christophe Moreno, Hendrik Reynaert, Len Verbeke, Mário Reis Álvares‐da‐Silva, Edison Roberto Parise, Cláudia P. Oliveira, Roberta Chaves Araújo, Ana de Lourdes Candolo Martinelli, Meredith A. Borman, Natasha Chandok, Magdy Elkhashab, Hughie F. Fraser, Kelly Kaita, Mang Ma, Paul Marotta, Alnoor Ramji, Edward Tam, Eric M. Yoshida, Mark G. Swain, Giada Sebastiani, Denis Petrunia, Armand Abergel, Rodolphe Anty, Marc Bourlière, Jérôme Boursier, Christophe Bureau, Laurent Castéra, François Habersetzer, Christophe Hézode, V. de Lédinghen, Vincent Leroy, V. Loustaud‐Ratti, Philippe Mathurin, Stanislas Pol, Fabien Zoulim, Holger Hinrichsen, Patrick Ingiliz, Frank Lammert, Michael Manns, Jörn M. Schattenberg, Ingolf Schiefke, Christian Trautwein, Stefan Zeuzem, Aric J. Hui, K Li, Vincent Wai‐Sun Wong, Subrat Kumar Acharya, Abhijit Chowdhury, Ajay Duseja, Dharmesh Kapoor, Shrikant Mukewar, Shiv Kumar Sarin, Samir Shah, S. Shalimar, Ajit Sood, BV Tantry, Ziv Ben‐Ari, Helena Katchman and 540 more - Journal of Hepatology 2020 cited by 466

  9. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis

    Authors: Ali Aminian, Abbas Al‐Kurd, Rickesha Wilson, James Bena, Hana Fayazzadeh, Tavankit Singh, Vance L. Albaugh, Faiz U. Shariff, Noe Rodriguez, Jian Jin, Stacy A. Brethauer, Srinivasan Dasarathy, Naim Alkhouri, Philip R. Schauer, Arthur J. McCullough, Steven E. Nissen - JAMA 2021 cited by 344

  10. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

    Authors: Naim Alkhouri, Robert Herring, Heidi Kabler, Zeid Kayali, Tarek Hassanein, Anita Kohli, Ryan S. Huss, Yanni Zhu, Andrew N. Billin, Lars Holm Damgaard, Kristine Buchholtz, Mette Skalshøi Kjær, Clare A. Balendran, Robert P. Myers, Rohit Loomba, Mazen Noureddin - Journal of Hepatology 2022 cited by 209

  11. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

    Authors: Beth A. Davison, Stephen A. Harrison, Gad Cotter, Naim Alkhouri, Arun J. Sanyal, Christopher Edwards, Jerry R. Colca, Julie Iwashita, Gary G. Koch, Howard C. Dittrich - Journal of Hepatology 2020 cited by 427

  12. Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

    Authors: Stephen A. Harrison, Mustafa R. Bashir, Sam E. Moussa, Kevin McCarty, Juan P. Frías, Rebecca Taub, Naim Alkhouri - Hepatology Communications 2021 cited by 187

  13. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

    Authors: Rohit Loomba, Mazen Noureddin, Kris V. Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H. Caldwell, Zachary Goodman, Ilan Wapinski, Murray B. Resnick, Andrew H. Beck, Dora Ding, Catherine Jia, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Keyur Patel, Brian B. Borg, Reem Ghalib, Heidi Kabler, John Poulos, Ziad Younes, Magdy Elkhashab, Tarek Hassanein, Rajalakshmi Iyer, Peter Ruane, Mitchell L. Shiffman, Simone I. Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, for the ATLAS Investigators - Hepatology 2020 cited by 278

  14. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

    Authors: Stephen A. Harrison, Samer Gawrieh, Katharine Roberts, Christopher J. Lisanti, Ryan B. Schwope, Katherine Cebe, Valérie Paradis, Pierre Bédossa, Jennifer Whitehead, Aymeric Labourdette, Véronique Miette, Stefan Neubauer, Céline Fournier, Angelo H. Paredes, Naim Alkhouri - Journal of Hepatology 2021 cited by 286

  15. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

    Authors: Quentin M. Anstee, Brent A. Neuschwander‐Tetri, Vincent Wai‐Sun Wong, Manal F. Abdelmalek, Gerardo Rodriguez‐Araujo, Henrik Landgren, Grace S. Park, Pierre Bédossa, Naim Alkhouri, Frank Tacke, Arun J. Sanyal - Clinical Gastroenterology and Hepatology 2023 cited by 148

  16. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

    Authors: Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary E. Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell L. Shiffman, Arun J. Sanyal, Adam Allgood, Harold Shlevin, R. G. Horton, Eliezer Zomer, William Irish, Zachary Goodman, Stephen A. Harrison, Peter G. Traber, Manal F. Abdelmalek, Luis A. Balart, Brian B. Borg, Naga Chalasani, Michael Charlton, Hari S. Conjeevaram, Michael Fuchs, Reem Ghalib, Pierre Gholam, Dina Halegoua‐De Marzio, Stephen A. Harrison, Christopher Jue, Nyingi Kemmer, Kris V. Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Mazen Noureddin, Angelo H. Paredes, Mary E. Rinella, Don C. Rockey, Miguel Rodriguez, Raymond A. Rubin, Michael Ryan, Arun J. Sanyal, Andrew Scanga, Thomas Sepe, Mitchell L. Shiffman, Mitchell L. Shiffman, Brent Tetri, Paul J. Thuluvath, Dawn M. Torres, John M. Vierling, Julia Wattacheril, Amanda Weiland, Donald L. Zogg - Gastroenterology 2019 cited by 344

  17. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement

    Authors: Mohammed Eslam, Naim Alkhouri, Pietro Vajro, Ulrich Baumann, Ram Weiss, Piotr Socha, Claude Marcus, Way Seah Lee, Déirdre Kelly, Gilda Porta, Mohamed Abdel‐Salam El‐Guindi, Anna Alisi, Jake P. Mann, Nezha Mouane, Louise A. Baur, Anil Dhawan, Jacob George - ˜The œLancet. Gastroenterology & hepatology 2021 cited by 272

  18. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

    Authors: Mazen Noureddin, Aarshi Vipani, Catherine Bresee, Tsuyoshi Todo, Irene Kim, Naim Alkhouri, Veronica Wendy Setiawan, Tram T. Tran, Walid S. Ayoub, Shelly C. Lu, Andrew S. Klein, Vinay Sundaram, Nicholas N. Nissen - The American Journal of Gastroenterology 2018 cited by 575

  19. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

    Authors: Mazen Noureddin, Emily Truong, Jeffrey Gornbein, Rola Saouaf, Maha Guindi, Tsuyoshi Todo, Nabil Noureddin, Ju Dong Yang, Stephen A. Harrison, Naim Alkhouri - Journal of Hepatology 2021 cited by 185

  20. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

    Authors: Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy, Naim Alkhouri, Mustafa R Bashir, Bradley Freilich, Anita Kohli, Arun Khazanchi, Muhammad Y Sheikh, Mark Leibowitz, Mary E Rinella, Mohammad S Siddiqui, Mark Kipnes, Sam E Moussa, Ziad H Younes, Meena Bansal, Seth J Baum, Brian Borg, Peter J Ruane, Paul J Thuluvath, Mildred Gottwald, Mujib Khan, Charles Chen, Liza Melchor-Khan, William Chang, Alex M DePaoli, Lei Ling, Hsiao D Lieu - ˜The œLancet. Gastroenterology & hepatology 2022 cited by 131

  21. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

    Authors: Mary E. Rinella, Hsiao D. Lieu, Kris V. Kowdley, Zachary Goodman, Naim Alkhouri, Eric Lawitz, Vlad Ratziu, Manal F. Abdelmalek, Vincent Wai‐Sun Wong, Ziad Younes, Aasim Sheikh, Donald Brannan, B. Freilich, Fernando E. Membreno, Marie Sinclair, Liza Melchor‐Khan, Arun J. Sanyal, Lei Ling, Stephen A. Harrison - Hepatology 2023 cited by 82

  22. A global research priority agenda to advance public health responses to fatty liver disease

    Authors: Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Marco Arrese, Ramón Bataller, Thomas Berg, Paul Brennan, Patrizia Burra, Graciela Castro‐Narro, Helena Cortez‐Pinto, Kenneth Cusi, Nikos Dedes, Ajay Duseja, Sven Francque, Hannes Hagström, Terry T.‐K. Huang, Dana Ivancovsky‐Wajcman, Achim Kautz, Christopher J. Kopka, Aleksander Krag, Veronica Miller, Philip N. Newsome, Mary E. Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C Wendy Spearman, Emmanuel Tsochatzis, Luca Valenti, Marcela Villota‐Rivas, Shira Zelber‐Sagi, Jörn M. Schattenberg, Vincent Wai‐Sun Wong, Zobair M. Younossi, Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Marco Arrese, Ramón Bataller, Thomas Berg, Paul Brennan, Patrizia Burra, Graciela Castro‐Narro, Helena Cortez‐Pinto, Kenneth Cusi, Nikos Dedes, Ajay Duseja, Sven Francque, Hannes Hagström, Terry T.‐K. Huang, Dana Ivancovsky‐Wajcman, Achim Kautz, Christopher J. Kopka, Aleksander Krag, Veronica Miller, Philip N. Newsome, Mary E. Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C. Wendy Spearman, Emmanuel Tsochatzis, Luca Valenti, Marcela Villota‐Rivas, Shira Zelber‐Sagi, Jörn M. Schattenberg, Vincent Wai‐Sun Wong, Zobair M. Younossi, Fredrik Åberg, Leon A. Adams, Khalid Al‐Naamani, Reda Albadawy, Zinaida Alexa, Michael Allison, Faisal Abdullatif Alnaser, Khalid Alswat, Mário Reis Álvares‐da‐Silva, Domenico Alvaro, Michele Alves‐Bezerra, Raúl J. Andrade, Quentin M. Anstee, Yaw Asante Awuku, Oidov Baatarkhuu, György Baffy, Shokhista Bakieva, Meena B. Bansal, Robert Barouki, Rachel L. Batterham and 241 more - Journal of Hepatology 2023 cited by 132

  23. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

    Authors: Zobair M. Younossi, Saleh A. Alqahtani, Khalid Alswat, Yusuf Yılmaz, Çağlayan Keklikkıran, Jesús Funuyet‐Salas, Manuel Romero‐Gómez, Jian‐Gao Fan, Ming‐Hua Zheng, Mohamed El‐Kassas, Laurent Castéra, Chun‐Jen Liu, Vincent Wai‐Sun Wong, Shira Zelber‐Sagi, Alina M. Allen, Brian Lam, Sombat Treeprasertsuk, Saeed Hameed, Hirokazu Takahashi, Takumi Kawaguchi, Jörn M. Schattenberg, Ajay Duseja, Philip N. Newsome, Sven Francque, C Wendy Spearman, Marlen I. Castellanos Fernández, Patrizia Burra, Stuart K. Roberts, Wah‐Kheong Chan, Marco Arrese, Marcelo Silva, Mary E. Rinella, Ashwani K. Singal, Stuart C. Gordon, Michael Fuchs, Naim Alkhouri, Kenneth Cusi, Rohit Loomba, Jane Ranagan, Wayne Eskridge, Achim Kautz, Janus P. Ong, Marcelo Kugelmas, Yuichiro Eguchi, M. Diago, Ming‐Lung Yu, Lynn H. Gerber, Lisa Fornaresio, Fatema Nader, Linda Henry, Andrei Racila, Pegah Golabi, Maria Stepanova, Patrizia Carrieri, Jeffrey V. Lazarus - Journal of Hepatology 2023 cited by 96

  24. Therapeutic pipeline in nonalcoholic steatohepatitis

    Authors: Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, Arun J. Sanyal - Nature Reviews Gastroenterology & Hepatology 2021 cited by 275